Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting COVID-19 and experiencing severe outcomes compared to individuals without HMs. This heightened risk is influenced by various factors, including the underlying malignancy, immunosuppressive treatments, and patient-related factors. Notably, immunosuppressive regimens commonly used for HM treatment can lead to the depletion of B cells and T cells, which is associated with increased COVID-19-related complications and mortality in these patients. As the pandemic transitions into an endemic state, it remains crucial to acknowledge and address the ongoing risk for individuals with HMs. In this review, we aim to summarize the current evidence to enhance our understanding of the impact of HMs on COVID-19 risks and outcomes, identify particularly vulnerable individuals, and emphasize the need for specialized clinical attention and management. Furthermore, the impaired immune response to COVID-19 vaccination observed in these patients underscores the importance of implementing additional mitigation strategies. This may include targeted prophylaxis and treatment with antivirals and monoclonal antibodies as indicated. To provide practical guidance and considerations, we present two illustrative cases to highlight the real-life challenges faced by physicians caring for patients with HMs, emphasizing the need for individualized management based on disease severity, type, and the unique circumstances of each patient.

1. Suligowski, R., & Ciupa, T. (2023). Five waves of the COVID-19 pandemic and green–blue spaces in urban and rural areas in Poland. Environmental Research, 216, Article 114662. https://doi.org/10.1016/j.envres.2022.114662
2. Martella, M., Peano, A., Politano, G., Onorati, R., & Gianino, M. M. (2023). Paediatric hospitalizations over three waves of COVID-19 (February 2020 to May 2021) in Italy: Determinants and rates. PeerJ, 11, Article e15492. https://doi.org/10.7717/peerj.15492
3. Anscombe, C., Lissauer, S., Thole, H., Rylance, J., Dula, D., Menyere, M., ... & Rylance, S. (2023). A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study. BMC Infectious Diseases, 23, Article 79. https://doi.org/10.1186/s12879-023-08031-x
4. Miyashita, K., Hozumi, H., Furuhashi, K., Nakatani, E., Inoue, Y., Yasui, H., ... & Suda, T. (2023). Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: A nationwide population-based study. Emerging Microbes & Infections, 12(1), Article 2155250. https://doi.org/10.1080/22221751.2022.2155250
5. Dhama, K., Nainu, F., Frediansyah, A., Yatoo, M. I., Mohapatra, R. K., Chakraborty, S., ... & Harapan, H. (2023). Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. Journal of Infection and Public Health, 16(1), 4–14. https://doi.org/10.1016/j.jiph.2022.11.024
6. Hsiao, Y. W., Bray, D. J., Taddese, T., Jiménez-Serratos, G., & Crain, J. (2023). Structure adaptation in Omicron SARS-CoV-2/hACE2: Biophysical origins of evolutionary driving forces. Biophysical Journal, 122(23), 4583–4595. https://doi.org/10.1016/j.bpj.2023.10.019
7. Seyler, L., Van Nedervelde, E., De Cock, D., Mann, C., Pien, K., Allard, S. D., ... & Dauby, N. (2023). Surfing the waves: Differences in hospitalised COVID-19 patients across 4 variant waves in a Belgian university hospital. Viruses, 15(3), Article 618. https://doi.org/10.3390/v15030618
8. Tanaka, H., Chubachi, S., Asakura, T., Namkoong, H., Azekawa, S., Otake, S., ... & Fukunaga, K. (2023). Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave—A nationwide study in Japan. International Journal of Infectious Diseases, 132, 84–88. https://doi.org/10.1016/j.ijid.2023.04.388
9. Malaeb, R., Haider, A., Abdulateef, M., Hameed, M., Daniel, U., Kabilwa, G., ... & t'Hoen, E. (2023). High mortality rates among COVID-19 intensive care patients in Iraq: Insights from a retrospective cohort study at Médecins Sans Frontières supported hospital in Baghdad. Frontiers in Public Health, 11, Article 1185330. https://doi.org/10.3389/fpubh.2023.1185330
10. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. (2023). Hematologic cancer incidence, survival, and prevalence. Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/uscs/about/data-briefs/no30-hematologic-incidence-survival-prevalence.htm
11. Smith, A., Howell, D., Patmore, R., Jack, A., & Roman, E. (2011). Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. British Journal of Cancer, 105(11), 1684–1692. https://doi.org/10.1038/bjc.2011.450
12. Zhang, N., Wu, J., Wang, Q., Liang, Y., Li, X., Chen, G., ... & Ju, Z. (2023). Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer Journal, 13(1), 1–13. https://doi.org/10.1038/s41408-023-00853-3
13. Shah, V., Ko, T., Zuckerman Ko, M., Vidler, J., Sharif, S., Mehra, V., ... & King's College Hospital Experience. (2020). Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies: King’s College Hospital experience. British Journal of Haematology, 190(3), e182–e186. https://doi.org/10.1111/bjh.16931
14. Zaki, A., Soomar, S. M., Khan, D. H., Shaharyar Sheikh, H., Iftikhar, R., Mir, A., ... & Multicenter Analysis from Pakistan. (2022). Outcomes of COVID-19 infection in patients with hematological malignancies: A multicenter analysis from Pakistan. PLOS ONE, 17(4), Article e0267139. https://doi.org/10.1371/journal.pone.0267139
15. Wood, W. A., Neuberg, D. S., Thompson, J. C., Tallman, M. S., Sekeres, M. S., Sehn, L. H., ... & ASH Research Collaborative Data Hub. (2020). Outcomes of patients with hematologic malignancies and COVID-19: A report from the ASH Research Collaborative Data Hub. Blood Advances, 4(23), 5966–5975. https://doi.org/10.1182/bloodadvances.2020003170
16. Manzano, J. M., Muthu, M., Kheder, E., Mohammed, A., Halm, J., Dickson, K., ... & Hospitalization Characteristics and Outcomes. (2022). Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center. Supportive Care in Cancer, 30(9), 7783–7788. https://doi.org/10.1007/s00520-022-07204-6
17. Asai, Y., Nomoto, H., Hayakawa, K., Matsunaga, N., Tsuzuki, S., Terada, M., ... & Ohmagari, N. (2022). Comorbidities as risk factors for severe disease in hospitalized elderly COVID-19 patients by different age-groups in Japan. Gerontology, 68(9), 1027–1037. https://doi.org/10.1159/000521398
18. Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., ... & He, J. (2020). Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. The Lancet Oncology, 21(3), 335–337. https://doi.org/10.1016/S1470-2045(20)30096-6
19. Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Rodrigues Falci, D., ... & COMET-ICE Investigators. (2022). Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: A randomized clinical trial. JAMA, 327(13), 1236–1246. https://doi.org/10.1001/jama.2022.2832
20. Castelo-Branco, L., Tsourti, Z., Gennatas, S., Rogado, J., Sekacheva, M., Viñal, D., ... & ESMO-CoCARE Registry. (2022). COVID-19 in patients with cancer: First report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). ESMO Open, 7(3), Article 100499. https://doi.org/10.1016/j.esmoop.2022.100499
21. Bange, E. M., Han, N. A., Wileyto, P., Kim, J. Y., Gouma, S., Robinson, J., ... & CD8+ T Cells. (2021). CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 27(7), 1280–1289. https://doi.org/10.1038/s41591-021-01386-7
22. Naimi, A., Yashmi, I., Jebeleh, R., Imani Mofrad, M., Azimian Abhar, S., Jannesar, Y., ... & Comorbidities and Mortality Rate. (2022). Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis. Journal of Clinical Laboratory Analysis, 36(6), Article e24387. https://doi.org/10.1002/jcla.24387
23. Pinato, D. J., Aguilar-Company, J., Ferrante, D., Hanbury, G., Bower, M., Salazar, R., ... & On COVID Registry Study. (2022). Outcomes of the SARS-CoV-2 Omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: Results from the retrospective, multicentre On COVID registry study. The Lancet Oncology, 23(7), 865–875. https://doi.org/10.1016/S1470-2045(22)00273-X
24. Martínez-López, J., De La Cruz, J., Gil-Manso, R., Alegre, A., Ortiz, J., Llamas, P., ... & COVID-19 Severity and Survival. (2023). COVID-19 severity and survival over time in patients with hematologic malignancies: A population-based registry study. Cancers, 15(5), Article 1497. https://doi.org/10.3390/cancers15051497
25. Pagano, L., Salmanton-García, J., Marchesi, F., López-García, A., Lamure, S., Itri, F., ... & EPICOVIDEHA. (2022). COVID-19 in vaccinated adult patients with hematological malignancies: Preliminary results from EPICOVIDEHA. Blood, 139(10), 1588–1592. https://doi.org/10.1182/blood.2021014641
26. Levi, M., & van Es, N. (2022). COVID-19 associated coagulopathy and thrombosis in cancer. Thrombosis Research, 213(Suppl. 1), S72–S76. https://doi.org/10.1016/j.thromres.2021.12.023
27. Cook, M. R., Dykes, K., White, K., Desale, S., Agrawal, R., Fernandez, S., ... & Thrombotic and Clinical Outcomes. (2022). Thrombotic and clinical outcomes in patients with hematologic malignancy and COVID-19. Clinical Lymphoma, Myeloma & Leukemia, 22(7), e452–e458. https://doi.org/10.1016/j.clml.2021.12.011
28. Connors, J. M., & Levy, J. H. (2020). Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis, 18(7), 1559–1561. https://doi.org/10.1111/jth.14849
29. Cuker, A., Tseng, E. K., Schünemann, H. J., Angchaisuksiri, P., Blair, C., Dane, K., ... & Anticoagulation for Thromboprophylaxis. (2022). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 6(17), 4975–4982. https://doi.org/10.1182/bloodadvances.2022007941
30. Hughes, A., & Yong, A. S. M. (2017). Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Frontiers in Immunology, 8, Article 469. https://doi.org/10.3389/fimmu.2017.00469
31. Hu, Y., Li, Q., Hou, M., Peng, J., Yang, X., & Xu, S. (2021). Magnitude and temporal trend of chronic myeloid leukemia: On the basis of the Global Burden of Disease study. JCO Global Oncology, 7, 1429–1441. https://doi.org/10.1200/GO.21.00192
32. Atallah, E., & Sweet, K. (2021). Treatment-free remission: The new goal in CML therapy. Current Hematologic Malignancy Reports, 16(5), 433–439. https://doi.org/10.1007/s11899-021-00653-5
33. Delgado, N., & Torres, A. (2022). What do we currently know about chronic myeloid leukemia (CML) and COVID-19? Current Oncology Reports, 24(5), 645–650. https://doi.org/10.1007/s11912-022-01217-1
34. Ludwig, H., Novis Durie, S., Meckl, A., Hinke, A., & Durie, B. (2020). Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. The Oncologist, 25(9), e1406–e1413. https://doi.org/10.1634/theoncologist.2020-0441
35. Zhou, L., Yu, Q., Wei, G., Wang, L., Huang, Y., Hu, K., ... & Measuring the Global Burden. (2021). Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer, 21(1), Article 606. https://doi.org/10.1186/s12885-021-08280-y
36. Martinez-Lopez, J., Hernandez-Ibarburu, G., Alonso, R., Sanchez-Pina, J. M., Zamanillo, I., Lopez-Muñoz, N., ... & Impact of COVID-19. (2021). Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer Journal, 11(12), Article 198. https://doi.org/10.1038/s41408-021-00588-z
37. Hjalgrim, H., & Jarrett, R. F. (2020). Epidemiology of Hodgkin lymphoma. In A. Engert & A. Younes (Eds.), Hodgkin lymphoma: A comprehensive overview (pp. 3–23). Springer International Publishing. https://doi.org/10.1007/978-3-030-32482-7_1
38. Huang, J., Rohatgi, A., Schneider, J., & Braunstein, M. (2020). Considerations for the management of oncology patients during the COVID-19 pandemic. Oncology (Williston Park), 34(10), 432–441. https://doi.org/10.46883/ONC.2020.3410.0432
39. Bonuomo, V., Ferrarini, I., Dell’Eva, M., Sbisà, E., Krampera, M., & Visco, C. (2021). COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World Journal of Virology, 10(6), 312–325. https://doi.org/10.5501/wjv.v10.i6.312
40. Visco, C., Marcheselli, L., Mina, R., Sassone, M., Guidetti, A., Penna, D., ... & Prognostic Model for Patients. (2022). A prognostic model for patients with lymphoma and COVID-19: A multicentre cohort study. Blood Advances, 6(2), 327–338. https://doi.org/10.1182/bloodadvances.2021005691
41. Harrington, P., Doores, K. J., Radia, D., O’Reilly, A., Lam, H. P. J., Seow, J., ... & Neutralising Antibody Responses. (2021). Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology, 194(6), 999–1006. https://doi.org/10.1111/bjh.17650
42. Rea, D., Mauro, M. J., Cortes, J. E., Jiang, Q., Pagnano, K. B., Ongondi, M., ... & iCMLf CANDID Study. (2020). COVID-19 in patients (pts) with chronic myeloid leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) study. Blood, 136(Suppl. 1), 46–47. https://doi.org/10.1182/blood-2020-143007
43. Breccia, M., Abruzzese, E., Bocchia, M., Bonifacio, M., Castagnetti, F., Fava, C., ... & Campus CML Survey. (2020). Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy: A Campus CML survey. Leukemia, 34(8), 2260–2261. https://doi.org/10.1038/s41375-020-0904-z
44. Neparidze, N., Wang, R., Zeidan, A. M., Podoltsev, N. A., Shallis, R. M., Ma, X., ... & Changes in Multiple Myeloma Treatment. (2022). Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia, 36(8), 2136–2139. https://doi.org/10.1038/s41375-022-01614-w
45. Garnica, M., Crusoe, E. D. Q., Ribeiro, G., Bittencourt, R., Magalhães, R. J. P., Zanella, K. R., ... & Grupo Brasileiro de Mieloma Múltiplo. (2023). COVID-19 in multiple myeloma patients: Frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality–cooperative registry from the Grupo Brasileiro de Mieloma Múltiplo (GBRAM). Hematology, Transfusion and Cell Therapy, 46(2), 153–160. https://doi.org/10.1016/j.htct.2023.09.001
46. Chu, Y., Liu, Y., Fang, X., Jiang, Y., Ding, M., Ge, X., ... & Epidemiological Patterns. (2023). The epidemiological patterns of non-Hodgkin lymphoma: Global estimates of disease burden, risk factors, and temporal trends. Frontiers in Oncology, 13, Article 1059914. https://doi.org/10.3389/fonc.2023.1059914
47. Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., ... & IFM 2009 Investigators. (2017). Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. New England Journal of Medicine, 376(14), 1311–1320. https://doi.org/10.1056/NEJMoa1611750
48. Li, W., Wang, D., Guo, J., Yuan, G., Yang, Z., Gale, R. P., ... & COVID-19 in Persons. (2020). COVID-19 in persons with chronic myeloid leukaemia. Leukemia, 34(7), 1799–1804. https://doi.org/10.1038/s41375-020-0870-5
49. Vakiti, A., & Mewawalla, P. (2024). Acute myeloid leukemia. StatPearls Publishing.
50. Modemann, F., Ghandili, S., Schmiedel, S., Weisel, K., Bokemeyer, C., & Fiedler, W. (2022). COVID-19 and adult acute leukemia: Our knowledge in progress. Cancers, 14(15), Article 3711. https://doi.org/10.3390/cancers14153711
51. Aureli, A., Marziani, B., Venditti, A., Sconocchia, T., & Sconocchia, G. (2023). Acute lymphoblastic leukemia immunotherapy treatment: Now, next, and beyond. Cancers, 15(13), Article 3346. https://doi.org/10.3390/cancers15133346
52. Cattaneo, C., Daffini, R., Pagani, C., Salvetti, M., Mancini, V., Borlenghi E., ... & Clinical Characteristics and Risk Factors. (2020). Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer, 126(23), 5069–5076. https://doi.org/10.1002/cncr.33126
53. Yigenoglu, T. N., Ata, N., Altuntas, F., Bascı, S., Dal, M. S., Korkmaz, S., ... & Outcome of COVID-19. (2021). The outcome of COVID-19 in patients with hematological malignancy. Journal of Medical Virology, 93(2), 1099–1104. https://doi.org/10.1002/jmv.26404
54. Galimberti, S., Petrini, M., Baratè, C., Ricci, F., Balducci, S., Grassi, S., ... & Tyrosine Kinase Inhibitors. (2020). Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2. Frontiers in Oncology, 10, Article 1428. https://doi.org/10.3389/fonc.2020.01428
55. Sisk, J. M., Frieman, M. B., & Machamer, C. E. (2018). Coronavirus S protein-induced fusion is blocked prior to hemifusion by ABL kinase inhibitors. Journal of General Virology, 99(5), 619–630. https://doi.org/10.1099/jgv.0.001047
56. Coleman, C. M., Sisk, J. M., Mingo, R. M., Nelson, E. A., White, J. M., & Frieman, M. B. (2016). Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. Journal of Virology, 90(19), 8924–8933. https://doi.org/10.1128/JVI.01429-16
57. Martínez-López, J., Mateos, M. V., Encinas, C., Sureda, A., Hernández-Rivas, J., Lopez de la Guía, A., ... & Multiple Myeloma and SARS-CoV-2. (2020). Multiple myeloma and SARS-CoV-2 infection: Clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer Journal, 10(10), Article 103. https://doi.org/10.1038/s41408-020-00372-z
58. Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K., ... & International Myeloma Society. (2020). Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set. Blood, 136(26), 3033–3040. https://doi.org/10.1182/blood.2020008150
59. Shang, Y., Wang, W., Liang, Y., Kaweme, N. M., Wang, Q., Liu, M., ... & Development of a Risk Assessment Model. (2022). Development of a risk assessment model for early grade $\ge$ 3 infection during the first 3 months in patients newly diagnosed with multiple myeloma based on a multicenter real-world analysis in China. Frontiers in Oncology, 12, Article 772015. https://doi.org/10.3389/fonc.2022.772015
60. Susek, K. H., Gran, C., Ljunggren, H., Alici, E., & Nahi, H. (2020). Outcome of COVID-19 in multiple myeloma patients in relation to treatment. European Journal of Haematology, 105(6), 751–754. https://doi.org/10.1111/ejh.13502
61. Wang, B., Van Oekelen, O., Mouhieddine, T. H., Del Valle, M. D., Richter, J., Cho, H. J., ... & Tertiary Center Experience. (2020). A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. Journal of Hematology & Oncology, 13(1), Article 94. https://doi.org/10.1186/s13045-020-00934-x
62. von Metzler, I., Campe, J., Huenecke, S., Raab, M. S., Goldschmidt, H., Schubert, R., ... & Cellular and Humoral Immunity. (2022). COVID-19 in multiple-myeloma patients: Cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view. Journal of Molecular Medicine, 100(3), 463–470. https://doi.org/10.1007/s00109-021-02166-x
63. Ibrahem, H. Y., Aly, D. H., Warda, A. E. A., Farahat, R. A., Youssef, R. M., Abdelhamid, M. H., ... & Efficacy of Tocilizumab. (2023). Efficacy of tocilizumab in management of COVID-19 patients admitted to intensive care units: A multicenter retrospective cohort study. Medicina, 59(1), Article 53. https://doi.org/10.3390/medicina59010053
64. Zheng, R., Mieth, K., Bennett, C., Miller, C., Anderson, L. D., Chen, M., ... & Clinical Features and Risk Stratification. (2023). Clinical features and risk stratification of multiple myeloma patients with COVID-19. Cancers, 15(14), Article 3598. https://doi.org/10.3390/cancers15143598
65. Krejci, M., Pour, L., Adam, Z., Sandecka, V., Stork, M., Sevcikova, S., ... & Outcome of COVID-19 Infection. (2021). Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: Single-center experience. Annals of Hematology, 100(10), 2541–2566. https://doi.org/10.1007/s00277-021-04597-2
66. Cook, G., John Ashcroft, A., Pratt, G., Popat, R., Ramasamy, K., Kaiser, M., ... & Real-world Assessment. (2020). Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. British Journal of Haematology, 190(5), e261–e266. https://doi.org/10.1111/bjh.16874
67. Ehsan, H., Britt, A., Voorhees, P. M., Paul, B., Bhutani, M., Varga, C., ... & Retrospective Review of Outcomes. (2023). Retrospective review of outcomes of multiple myeloma (MM) patients with COVID-19 infection (two-center study). Clinical Lymphoma, Myeloma & Leukemia, 23(4), 273–278. https://doi.org/10.1016/j.clml.2023.01.002
68. Hultcrantz, M., Richter, J., Rosenbaum, C. A., Patel, D., Smith, E. L., Korde, N., ... & COVID-19 Infections and Clinical Outcomes. (2020). COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York city: A cohort study from five academic centers. Blood Cancer Discovery, 1(3), 234–243. https://doi.org/10.1158/2643-3230.BCD-20-0112
69. Tığlıoğlu, P., Albayrak, M., Tığlıoğlu, M., Öztürk, H. B. A., Aras, M. R., Sağlam, B., ... & Outcome of COVID-19. (2022). The outcome of COVID-19 in patients with hematological malignancy. Memo - Magazine of European Medical Oncology, 15(1), 83–89. https://doi.org/10.1007/s12254-021-00778-9
70. Oliva, A., Curtolo, A., Volpicelli, L., Cancelli, F., Borrazzo, C., Cogliati Dezza, F., ... & Clinical Course of Coronavirus. (2022). Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: Results from a case-control study. Infection, 50(5), 1373–1382. https://doi.org/10.1007/s15010-022-01826-6
71. Duléry, R., Lamure, S., Delord, M., Di Blasi, R., Chauchet, A., Hueso, T., ... & Prolonged In-hospital Stay. (2021). Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. American Journal of Hematology, 96(8), 934–944. https://doi.org/10.1002/ajh.26215
72. Pagano, L., Salmanton-García, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., ... & EPICOVIDEHA Survey. (2021). COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology & Oncology, 14(1), Article 168. https://doi.org/10.1186/s13045-021-01177-0
73. Marchesi, F., Salmanton-García, J., Emarah, Z., Piukovics, K., Nucci, M., López-García, A., ... & EPICOVIDEHA Survey. (2023). COVID-19 in adult acute myeloid leukemia patients: A long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 108(1), 22–33. https://doi.org/10.3324/haematol.2022.281319
74. Goldman, J. D., Robinson, P. C., Uldrick, T. S., & Ljungman, P. (2021). COVID-19 in immunocompromised populations: Implications for prognosis and repurposing of immunotherapies. Journal for ImmunoTherapy of Cancer, 9(6), Article e002630. https://doi.org/10.1136/jitc-2021-002630
75. Grivas, P., Khaki, A. R., Wise-Draper, T. M., French, B., Hennessy, C., Hsu, C. Y., ... & COVID-19 and Cancer Consortium. (2021). Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium. Annals of Oncology, 32(6), 787–800. https://doi.org/10.1016/j.annonc.2021.02.024
76. Chavez-MacGregor, M., Lei, X., Zhao, H., Scheet, P., & Giordano, S. H. (2022). Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncology, 8(1), 69–78. https://doi.org/10.1001/jamaoncol.2021.5148
77. Várnai, C., Palles, C., Arnold, R., Curley, H. M., Purshouse, K., Cheng, V. W. T., ... & UK Coronavirus Cancer Monitoring Project. (2022). Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Network Open, 5(2), Article e220130. https://doi.org/10.1001/jamanetworkopen.2022.0130
78. Sharafeldin, N., Bates, B., Song, Q., Madhira, V., Yan, Y., Dong, S., ... & National COVID Cohort Collaborative. (2021). Outcomes of COVID-19 in patients with cancer: Report from the National COVID Cohort Collaborative (N3C). Journal of Clinical Oncology, 39(20), 2232–2246. https://doi.org/10.1200/JCO.21.01074
79. Lee, C. Y., Shah, M. K., Hoyos, D., Solovyov, A., Douglas, M., Taur, Y., ... & Prolonged SARS-CoV-2 Infection. (2022). Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discovery, 12(1), 62–73. https://doi.org/10.1158/2159-8290.CD-21-1033
80. Cheng, G. S., & Evans, S. E. (2022). The paradox of immunosuppressants and COVID-19. European Respiratory Journal, 59(3), Article 2102828. https://doi.org/10.1183/13993003.02828-2021
81. Ripa, M., Galli, L., Poli, A., Oltolini, C., Spagnuolo, V., Mastrangelo, A., ... & Secondary Infections in Patients. (2021). Secondary infections in patients hospitalized with COVID-19: Incidence and predictive factors. Clinical Microbiology and Infection, 27(3), 451–457. https://doi.org/10.1016/j.cmi.2020.10.021
82. Zappasodi, P., Cattaneo, C., Valeria Ferretti, V., Mina, R., José María Ferreri, A., Merli, F., ... & ITA-HEMA-COV. (2022). Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. Hematological Oncology, 40(5), 846–856. https://doi.org/10.1002/hon.3072
83. Casetti, I. C., Borsani, O., & Rumi, E. (2022). COVID-19 in patients with hematologic diseases. Biomedicines, 10(12), Article 3069. https://doi.org/10.3390/biomedicines10123069
84. Pinato, D. J., Tabernero, J., Bower, M., Scotti, L., Patel, M., Colomba, E., ... & On Covid Retrospective. (2021). Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: Evidence from the On Covid retrospective, multicentre registry study. The Lancet Oncology, 22(12), 1669–1680. https://doi.org/10.1016/S1470-2045(21)00572-8
85. Chen, S., Guan, F., Candotti, F., Benlagha, K., Camara, N. O. S., Herrada, A. L., ... & Role of B Cells. (2022). The role of B cells in COVID-19 infection and vaccination. Frontiers in Immunology, 13, Article 988536. https://doi.org/10.3389/fimmu.2022.988536
86. Shah, N., Mustafa, S. S., & Vinh, D. C. (2023). Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Critical Reviews in Oncology/Hematology, 181, Article 103896. https://doi.org/10.1016/j.critrevonc.2022.103896
87. Barahona-Correa, J. E., Rueda-Ortiz, C., López, M. J., & Gualtero, S. (2023). COVID-19 infection during blinatumomab therapy: Is safety a dilemma? SAGE Open Medical Case Reports, 11, Article 2050313X221148548. https://doi.org/10.1177/2050313X221148548
88. Cesaro, S., Ljungman, P., Mikulska, M., Hirsch, H. H., von Lilienfeld-Toal, M., Cordonnier, C., ... & Recommendations for the Management. (2022). Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia, 36(6), 1467–1473. https://doi.org/10.1038/s41375-022-01536-7
89. Salmanton-García, J., Marchesi, F., Farina, F., Weinbergerová, B., Itri, F., Dávila-Valls, J., ... & EPICOVIDEHA Insights. (2024). Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine, 71, Article 102553. https://doi.org/10.1016/j.eclinm.2024.102553
90. Cesaro, S., Mikulska, M., Hirsch, H. H., Styczynski, J., Meylan, S., Cordonnier, C., ... & Update of Recommendations. (2023). Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia, 37(10), 1933–1938. https://doi.org/10.1038/s41375-023-01990-2
91. Perry, C., Luttwak, E., Balaban, R., Shefer, G., Morales, M. M., Aharon, A., ... & Efficacy of the BNT162b2. (2021). Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Advances, 5(16), 3053–3061. https://doi.org/10.1182/bloodadvances.2021004094
92. Blennow, O., Salmanton-García, J., Nowak, P., Itri, F., Van Doesum, J., López-García, A., ... & Outcome of Infection. (2022). Outcome of infection with Omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. American Journal of Hematology, 97(10), E312–E317. https://doi.org/10.1002/ajh.26651
93. Del Poeta, G., Bomben, R., Polesel, J., Rossi, F. M., Pozzo, F., Zaina, E., ... & COVID-19 Vaccination Evaluation. (2021). COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. Hematological Oncology, 39(5), 712–714. https://doi.org/10.1002/hon.2891
94. Corti, C., Antonarelli, G., Scotté, F., Spano, J. P., Barrière, J., Michot, J. M., ... & Seroconversion Rate After Vaccination. (2022). Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Annals of Oncology, 33(2), 158–168. https://doi.org/10.1016/j.annonc.2021.10.014
95. Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., ... & Seroconversion Rates Following. (2021). Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell, 39(8), 1081–1090.e2. https://doi.org/10.1016/j.ccell.2021.06.002
96. Morawska, M. (2022). Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. European Journal of Haematology, 108(2), 91–98. https://doi.org/10.1111/ejh.13715
97. Aleman, A., Upadhyaya, B., Tuballes, K., Kappes, K., Gleason, C. R., Beach, K., ... & Variable Cellular Responses. (2021). Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 39(11), 1442–1444. https://doi.org/10.1016/j.ccell.2021.09.015
98. Oekelen, O. V., Gleason, C. R., Agte, S., Srivastava, K., Beach, K. F., Aleman, A., ... & Highly Variable SARS-CoV-2. (2021). Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell, 39(8), 1028–1030. https://doi.org/10.1016/j.ccell.2021.06.014
99. Wiedmeier-Nutor, J. E., Iqbal, M., Rosenthal, A. C., Bezerra, E. D., Garcia-Robledo, J. E., Bansal, R., ... & Response to COVID-19. (2023). Response to COVID-19 vaccination post-CAR T therapy in patients with non-Hodgkin lymphoma and multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia, 23(6), 456–462. https://doi.org/10.1016/j.clml.2023.02.012
100. Zhang, T., Tian, W., Wei, S., Lu, X., An, J., He, S., ... & Multidisciplinary Recommendations. (2023). Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Experimental Hematology & Oncology, 12(1), Article 66. https://doi.org/10.1186/s40164-023-00427-4
101. Giesen, N., Busch, E., Schalk, E., Beutel, G., Rüthrich, M. M., Hentrich, M., ... & AGIHO Guideline. (2023). AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. European Journal of Cancer, 181, 102–118. https://doi.org/10.1016/j.ejca.2022.11.026
102. Owen, C., Robinson, S., Christofides, A., & Sehn, L. H. (2022). A Canadian perspective: Monoclonal antibodies for pre- and post-exposure protection from COVID-19 in vulnerable patients with hematological malignancies. Current Oncology, 29(6), 3940–3949. https://doi.org/10.3390/curroncol29060315
103. Levin, M. J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., ... & PROVENT Study Group. (2022). Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19. New England Journal of Medicine, 386(23), 2188–2200. https://doi.org/10.1056/NEJMoa2116620
104. O’Brien, M. P., Forleo-Neto, E., Musser, B. J., Isa, F., Chan, K. C., Sarkar, N., ... & COVID-19 Phase 3 Prevention Trial Team. (2021). Subcutaneous REGEN-COV antibody combination to prevent COVID-19. New England Journal of Medicine, 385(13), 1184–1195. https://doi.org/10.1056/NEJMoa2109682
105. Stuver, R., Shah, G. L., Korde, N. S., Roeker, L. E., Mato, A. R., Batlevi, C. L., ... & Activity of AZD7442. (2022). Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell, 40(6), 590–591. https://doi.org/10.1016/j.ccell.2022.05.007
106. Najjar-Debbiny, R., Gronich, N., Weber, G., Khoury, J., Amar, M., Stein, N., ... & Effectiveness of Paxlovid. (2023). Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clinical Infectious Diseases, 76(3), e342–e349. https://doi.org/10.1093/cid/ciac443
107. Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., ... & PINETREE Investigators. (2022). Early remdesivir to prevent progression to severe COVID-19 in outpatients. New England Journal of Medicine, 386(4), 305–315. https://doi.org/10.1056/NEJMoa2116846
108. Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., ... & EPIC-HR Investigators. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine, 386(15), 1397–1408. https://doi.org/10.1056/NEJMoa2118542
109. Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., ... & MOVEL-OUT Study Group. (2022). Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. New England Journal of Medicine, 386(6), 509–520. https://doi.org/10.1056/NEJMoa2116044
110. Giesen, N., Sprute, R., Rüthrich, M., Khodamoradi, Y., Mellinghoff, S. C., Beutel, G., ... & Evidence-based Management of COVID-19. (2020). Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). European Journal of Cancer, 140, 86–104. https://doi.org/10.1016/j.ejca.2020.09.009